IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Xunfei Healthcare 02506.HK	Application Software	82.8	50	N/A	2024/12/23	Data is not available	2024/12/30
InnoScience 02577.HK	Semiconductors & Semiconductor Equipment	30.86-33.66	100	3,400	2024/12/23	Data is not available	2024/12/30
HealthyWay 02587.HK	Health Care Services	7.8-8.8	500	4,444	2024/12/23	Data is not available	2024/12/30

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Xunfei Healthcare
02506.HK

Application Software

82.8

N/A

2024/12/23

Data is not available

2024/12/30

InnoScience
02577.HK

Semiconductors & Semiconductor Equipment

30.86-33.66

100

3,400

2024/12/23

Data is not available

2024/12/30

HealthyWay
02587.HK

Health Care Services

7.8-8.8

500

4,444

2024/12/23

Data is not available

2024/12/30

Summary

We are an innovative neuro-interventional medical device company with an established leadership position in the neuro-intervention market in China by virtue of our broad portfolio of both commercialized products and product candidates. Our product portfolio includes both neuro-interventional and cardiac medical devices. Leveraging our capabilities in R&D, manufacturing and commercialization, we strive to reduce the mortality rate and improve prognosis of stroke in China and worldwide through the commercialization of our product candidates. Our two Core Products are CaptorTM thrombectomy device (“Captor”), which is for acute ischemic stroke and has been commercialized in China, and left atrial appendage (LAA) occluder, which is for atrial fibrillation and is in NMPA registration review. Founded in June 2016, we have a broad portfolio of four commercialized products and 19 approved products and product candidates in China covering all major stroke subtypes and surgical pathways in the neuro-interventional field, while our ischemic stroke prevention product candidates also allow us to capture demands from the cardiac market. We have developed all of our products and product candidates in-house from design stage to the subsequent product registration and commercialization. Our portfolio extends from the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis, to the treatment of hemorrhagic stroke. As of the Latest Practicable Date, we had commercialized four ischemic stroke treatment devices forming a complete product suite for stent retrieving thrombectomy procedures. We commenced sales for the thrombectomy device, the distal access catheter and microcatheter in the product suite in 2020 and for our balloon guiding catheter in April 2021. Additionally, we expect to commercialize nine product candidates in 2021 and commercialize another 10 product candidates between 2022 and 2025, including the global-first sirolimus intracranial drug- eluting balloon catheter for intracranial stenosis treatment, thereby further expanding and diversifying our product offerings for the unmet and differentiated needs of stroke patients. Stroke is a leading cause of death and disability globally. In China, stroke was the top cause of death in 2019 as the incidence rate of stroke recorded continued increase in recent years largely driven by the aging of the Chinese population. Neuro-interventional technology innovations in recent years are revolutionizing the therapeutic and preventive practices in the field of stroke, causing a fundamental shift from the traditional anticoagulant drug treatment and intravenous thrombolysis to the new neuro-interventional procedures with proven safety and significantly enhanced efficacy according to papers published by third parties in internationally renowned scientific journals. According to CIC, the patient expenditure on medication therapy, open surgery and neuro-interventional procedures for ischemic stroke was RMB493.4 million, RMB1,273.3 million and RMB3,056.0 million, respectively; the patient expenditure by the same treatment options for hemorrhagic stroke was RMB1,118.7 million, RMB2,689.2 million and RMB4,195.1 million, respectively; and the patient expenditure by the same treatment options for intracranial stenosis was RMB63.9 million, RMB170.5 million and RMB2,060.0 million, respectively, in China in 2019. Our innovative and comprehensive product portfolio, with one global-first (sirolimus intracranial drug-eluting balloon catheter) and a number of domestic-first (Captor and Fullblock balloon guiding catheter) neuro- interventional devices, places us at the forefront of such fundamental shift. China has a large patient pool of stroke. The number of stroke patients in China reached 14.8 million in 2019, including 11.9 million ischemic stroke patients and 2.9 million hemorrhagic stroke patients, and the annual incidence (occurrence of new cases of disease) of ischemic stroke reached 2.3 million in 2019, according to CIC. On the other hand, the penetration rate (measured by the number of procedures as a percentage of the number of patients eligible for such procedures) of neuro-interventional procedures in China was relatively low as compared to that of the developed countries. In the U.S., due to the American Heart Association (AHA) guideline’s recognition in 2015 of thrombectomy as the first-line treatment for ischemic stroke and the technology advancements, the penetration rate of thrombectomy procedures increased rapidly from 1.4% in 2015 to 11.8% in 2019. By comparison, the penetration rate of thrombectomy procedures in China stood at a mere 1.7% in 2019 but is expected to increase to 42.9% in 2030, benefiting from a combination of technology innovation, favorable government policies and rising per capita income and healthcare expenditure. As a front-runner in the China neuro-interventional device market, we aim to capture such growth in thrombectomy procedures between now and 2030 and solidify our established leadership position in the neuro-intervention market in China by virtue of our broad portfolio of both commercialized products and product candidates. Source: HeartCare-B (06609) Prospectus (IPO Date : 2021/08/10)
Listing Market	MAIN
Industry	Biotechnology
Background	H Shares
Major Business Area	N/A

Corporate Information

Substantial Shareholders	WANG Guohui (Total share: 29.20%); (H share: 25.83%) LYFE Capital Management Limited (Total share: 13.64%); (H share: 16.78%) Ding Kui & Associates (Total share: 8.15%); (H share: 7.55%) ZHANG Kun (Total share: 8.07%); (H share: 4.96%) Temasek Holdings (Private) Limited (Total share: 4.55%); (H share: 5.60%)
Directors	WANG Guohui (Chairman and Chief Executive Officer and Executive Director) ZHANG Kun (Deputy General Manager and Executive Director) Wei Jiawei (Executive Director) Ding Kui (Non-Executive Director) Chen Shaoxiong (Non-Executive Director) CHEN Gang (Non-Executive Director) FENG Xiangqian (Independent Non-Executive Director) GONG Ping (Independent Non-Executive Director) GUO Shaomu (Independent Non-Executive Director)
Company Secretary	Zhang Han KWOK Siu Ying, Sarah
Principal Bankers	China Merchants Bank
Solicitors	All Bright Law Offices O Melveny & Myers LLP
Auditors	Ernst & Young
Registered Office	Room 1901, 19th Floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http://www.heartcare.com.cn
Email Address	info@heartcare.com.cn
Tel No	(86 21) 5897-5056
Fax No

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates